Study drug RO7589831 for MSI/dMMR solid tumors (BP44474) - Clinical Trial

or email

gi-oncology-cru@dm.duke.edu

What is the Purpose of this Study?

We are doing this study to find out if an experimental drug called RO7589831 (the study drug) is a safe and effective option for cancers with solid tumors. We also want to find out what the best dose of the study drug is in this study.

What is the Condition Being Studied?

Advanced Solid Tumors

Who Can Participate in the Study?

Adults ages 18+ who:

Are diagnosed with advanced cancer that worsened after at least 1 prior line of standard therapy

Have had a tumor sample test positive for microsatellite instability or mismatch repair deficiency

For more information about this study, please contact the study team at 919-668-1861 or gi-oncology-cru@dm.duke.edu.

Grupo etario

Adultos

What is Involved?

Si elige unirse a este estudio, podrá:

Take the study drug every day (it is taken by mouth)
Hágase biopsia del tumor
Give blood and urine samples
Realice tomografías computarizadas o resonancias magnéticas de manera regular.

Study Details

Full Title

[BP44474] A phase I, open-label study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and anti-tumor activity of RO7589831 as monotherapy and in combination with pembrolizumab in participants with advanced solid tumors harboring microsatellite instability (MSI) and/or deficient mismatch repair (dMMR)

Principal Investigator